SCHEMBL4902292

SCHEMBL4902292

CN1CCN(Cc2ccc(C(=O)Nc3ccc(Nc4nccc(-c5cccnc5)n4)cc3)cc2)CC1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 20/20 0.86
BCR P11274 14/20 0.86
PDGFRA P16234 3/20 0.86
PDGFRB P09619 2/20 0.86
SRC P12931 2/20 0.86
SYK P43405 2/20 0.86
KIT P10721 12/20 0.82
ABL2 P42684 7/20 0.82
LYN P07948 3/20 0.82
PLK4 O00444 1/20 0.82
DDX3X O00571 1/20 0.82
GAK O14976 1/20 0.82
SLC22A2 O15244 1/20 0.82
MAPK13 O15264 1/20 0.82
CA12 O43570 1/20 0.82
SLC22A3 O75751 1/20 0.82
ABCB11 O95342 1/20 0.82
EGFR P00533 1/20 0.82
CA1 P00915 1/20 0.82
CA2 P00918 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3860877 0.97 ABL1 (0.81) ABL1BCRPDGFRAPDGFRBSRC
Hydrochloric Acid SCHEMBL3867300 0.96 ABL1 (0.79) ABL1BCRPDGFRAPDGFRBSRC
Acetic Acid SCHEMBL3858375 0.94 ABL1 (0.77) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL3868282 0.94 ABL1 (0.79) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL9485 0.92 ABL1 (1.00) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL4901725 0.91 ABL1 (0.72) ABL1BCRPDGFRAPDGFRBSRC
Imatinib SCHEMBL29351601 0.90 ABL1 (1.00) ABL1BCRPDGFRAPDGFRBSRC
SCHEMBL13845837 0.90 ABL1 (0.88) ABL1BCRPDGFRAPDGFRBSRC
Imatinib SCHEMBL29355523 0.90 ABL1 (1.00) ABL1BCRPDGFRAPDGFRBSRC
Imatinib SCHEMBL2236091 0.90 ABL1 (1.00) ABL1BCRPDGFRAPDGFRBSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US claimed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP claimed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO claimed
US-20080187575-A1 Pyrimidine Derivatives VICHEM CHEMIE KFT (HU) 2008-08-07 US disclosed
EP-1786781-A2 PYRIMIDINE DERIVATIVES GPC Biotech AG (DE) 2007-05-23 EP disclosed
WO-2006021458-A2 PYRIMIDINE DERIVATIVES GPC BIOTECH AG (DE) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080187575-A1 Pyrimidine Derivatives TYMP, TDP1, PNP ABL1 2843/4885BCR 2315/4885PDGFRA 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.